NASDAQ:ANGN Angion Biomedica (ANGN) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ANGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.00▼$10.0052-Week Range N/AVolume224,800 shsAverage Volume86,718 shsMarket Capitalization$30.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Angion Biomedica alerts: Email Address Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About Angion Biomedica Stock (NASDAQ:ANGN)Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.Read More Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now ANGN Stock News HeadlinesJune 1, 2023 | finance.yahoo.comAngion Biomedia Corp. Announces 1-for-10 Reverse Stock SplitMay 2, 2023 | marketwatch.com8-K: Angion Biomedica Corp.April 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 27, 2023 | finance.yahoo.comCompanies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite RiskyApril 11, 2023 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVAApril 6, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, ANGN, TIGMarch 4, 2023 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLI, DCT, ANGNFebruary 24, 2023 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, OSH, IAAApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.January 22, 2023 | benzinga.comMoore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law FirmJanuary 18, 2023 | benzinga.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Angion Biomedica Corp. - ANGNJanuary 17, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Angion Biomedica Corp. MergerJanuary 17, 2023 | marketwatch.comAngion Biomedica Shares Tumble Premarket on Elicio Tie-Up >ANGNJanuary 17, 2023 | technews.tmcnet.comANGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Angion Biomedica Corp. Is Fair to ShareholdersDecember 27, 2022 | finance.yahoo.comBullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)December 22, 2022 | finanznachrichten.deAngion Biomedica Corp.: Angion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsDecember 22, 2022 | finance.yahoo.comAngion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNovember 29, 2022 | nasdaq.comNabriva (NBRV) Posts Positive Data From Cystic Fibrosis StudyNovember 29, 2022 | nasdaq.comAxsome (AXSM) Gains as Alzheimer's Agitation Study Meets GoalNovember 24, 2022 | msn.comReasons to Add Immunovant (IMVT) Stock to Your Portfolio NowNovember 17, 2022 | nasdaq.comImmunovant (IMVT) Rises More Than 150% in 3 Months: Here's HowNovember 10, 2022 | finance.yahoo.comJazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive SalesNovember 4, 2022 | finance.yahoo.comKaruna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 LossNovember 1, 2022 | finance.yahoo.comLilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 ViewOctober 13, 2022 | finance.yahoo.comIs Angion Biomedica (NASDAQ:ANGN) In A Good Position To Deliver On Growth Plans?September 24, 2022 | finance.yahoo.comAngion Biomedica Corp. (ANGN)September 12, 2022 | msn.comAngion Biomedica's Return On Capital Employed OverviewSee More Headlines Receive ANGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ANGN CUSIPN/A CIK1601485 Webwww.angion.com Phone415-655-4899FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,810,000.00 Net MarginsN/A Pretax Margin-4,456.97% Return on Equity-47.53% Return on Assets-40.55% Debt Debt-to-Equity RatioN/A Current Ratio20.00 Quick Ratio20.00 Sales & Book Value Annual Sales$2.30 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / BookN/AMiscellaneous Outstanding Shares30,110,000Free Float24,182,000Market Cap$30.11 million OptionableNot Optionable Beta0.60 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Jay R. Venkatesan M.B.A. (Age 51)M.D., Ph.D., Pres, CEO & Chairman Comp: $619.88kMs. Jennifer J. Rhodes J.D. (Age 53)Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec. Comp: $453.04kMr. Gregory S. Curhan (Age 61)Chief Financial Officer Mr. Daniel IazzettiVP of HRKey CompetitorsOrphazyme A/SNASDAQ:ORPHTevogen BioNASDAQ:TVGNLianBioNASDAQ:LIANEnlivex TherapeuticsNASDAQ:ENLVCelyad OncologyNASDAQ:CYADView All Competitors ANGN Stock Analysis - Frequently Asked Questions How were Angion Biomedica's earnings last quarter? Angion Biomedica Corp. (NASDAQ:ANGN) announced its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) EPS for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The firm had revenue of $1.46 million for the quarter, compared to the consensus estimate of $1.08 million. When did Angion Biomedica's stock split? Angion Biomedica's stock reverse split on the morning of Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Angion Biomedica IPO? Angion Biomedica (ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers. This page (NASDAQ:ANGN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Angion Biomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
